Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
招募中
1
100.0%
暂无批准数据
- A minimally invasive endoscopic procedure called duodenal mucosal resurfacing helped patients maintain over 80% of their weight loss after discontinuing GLP-1 drugs like tirzepatide. - Interim results from a clinical trial of 45 participants showed those receiving the procedure regained only 7 pounds compared to 40% more weight regain in the control group at six months. - The procedure uses targeted heat to destroy and regenerate the duodenal lining, potentially resetting metabolism to maintain post-GLP-1 weight loss benefits. - Trial sponsor Fractyl Health expects to release complete six-month data and apply for regulatory approval by the end of 2026.
- The Trump administration launched executive orders in 2025 to bolster domestic pharmaceutical manufacturing capacity, including building a stockpile of active pharmaceutical ingredients from U.S. suppliers where possible. - Industry experts warn that the U.S. leads the world in generic drug shortages due to heavy reliance on foreign suppliers, with particular vulnerabilities in antibiotic and key starting material supply chains. - Advanced manufacturing technologies and automation are emerging as critical solutions, though experts caution that quality control systems must evolve to match increased production speeds. - The cell and gene therapy sector achieved breakthrough manufacturing improvements in 2025, with the FDA's Advanced Manufacturing Technologies program accelerating regulatory support for innovative production methods.
- Fractyl Health's RJVA-001, a single-dose pancreatic gene therapy, demonstrated durable metabolic improvements in diabetic mouse models with significantly lower systemic GLP-1 exposure than conventional GLP-1 drugs. - The therapy mimics natural hormone regulation through nutrient-responsive GLP-1 secretion from pancreatic beta cells, potentially addressing durability, adherence, and tolerability challenges seen with current GLP-1 medications. - Endoscopic ultrasound-guided delivery achieved targeted pancreatic expression with no observed toxicity in large animal models, positioning RJVA-001 for first-in-human studies with CTA submission expected by June 2025.
• Forge Biologics will provide AAV development and cGMP manufacturing services for Fractyl Health's Rejuva pancreatic gene therapy platform targeting obesity and type 2 diabetes. • The collaboration leverages Forge's proprietary FUEL™ platform, including HEK293 suspension Ignition Cells™ and pEMBR™ 2.0 adenovirus helper plasmid, to enable more efficient and scalable manufacturing. • Fractyl's Rejuva platform, currently in preclinical development, aims to develop treatments that prevent and reverse metabolic diseases rather than simply managing symptoms.
- WVU Medicine is spearheading the REMAIN-1 clinical trial investigating Revita DMR, a minimally invasive procedure designed to maintain weight loss in patients discontinuing GLP-1 medications. - The innovative procedure uses hydrothermal ablation to regenerate the duodenal lining, potentially stimulating natural GLP-1 production and preventing weight regain after stopping medications like Mounjaro and Wegovy. - Initial results from the REVEAL-1 trial showed promising outcomes, with patients maintaining their 15% weight loss four weeks after the procedure, leading to expanded investigation in the current multicenter study.
- Fractyl Health's REVEAL-1 study shows promising initial results for weight maintenance after discontinuing GLP-1 drugs using the Revita procedure. - The first patient in the REVEAL-1 cohort maintained a 15% total body weight loss one month after discontinuing tirzepatide and undergoing the Revita procedure. - Enrollment in the REMAIN-1 pivotal study is progressing rapidly, indicating strong interest in solutions for post-GLP-1 weight maintenance. - Fractyl Health is prioritizing its Revita and Rejuva programs, focusing on weight maintenance and gene therapy for obesity and type 2 diabetes.
- Intensity Therapeutics doses first patient in Phase 2 trial for triple-negative breast cancer and progresses Phase 3 sarcoma study. - Fractyl Health reports progress in Revita and Rejuva platforms, with key data readouts expected in late 2024 and 2025. - Fractyl Health's REMAIN-1 study is evaluating Revita's efficacy in maintaining weight loss after GLP-1 therapy discontinuation. - Both companies highlight financial results, with Intensity focusing on INT230-6 development and Fractyl on Revita and Rejuva.
- Fractyl Health's Revita procedure demonstrated a nearly 13% total body weight loss at 12 months in patients with obesity and Type 2 Diabetes. - The German Real-World Registry showed a substantial decrease in median HbA1c from 9.6% to 7.2% at 12 months post-Revita in poorly controlled patients. - Most patients in the registry maintained or decreased their glucose-lowering medications, suggesting Revita's potential to alter the treatment paradigm. - The Revita procedure was well-tolerated, with no procedure-related adverse safety events observed, highlighting its safety profile in real-world use.
- Fractyl Health's Revita System has been granted Breakthrough Device Designation by the FDA for weight maintenance after stopping GLP-1 drugs. - The Revita System is an outpatient endoscopic procedure targeting the duodenal lining to improve metabolism and blood glucose levels. - The REMAIN-1 pivotal study is underway to evaluate Revita's efficacy in maintaining weight loss, with data expected in late 2024 and mid-2025. - Breakthrough Device Designation expedites FDA review and may accelerate reimbursement decisions by the Centers for Medicare & Medicaid Services.
